Corinne Faivre-Finn, FRCR, MD, PhD of University of Manchester and the Christie NHS Foundation Trust, UK discusses key messages from the small-cell lung cancer (SCLC) session. Experts, who participated in the session talked about a lack of progress with systemic therapy, targeted agents, and chemotherapy. However, as Dr Faivre-Finn points out, a lot of progress has been made in SCLC with radiotherapy treatments due to better integration of radiotherapy and systemic therapy. Results of the CONVERT trial show better survival and less toxicity. Moreover, there is evidence that prophylactic cranial irradiation improves survival, with recent data from a European trial showing that thoracic radiotherapy in addition to cranial irradiation improves survival in extensive-stage SCLC patients without liver metastases and with less than 3 metastatic sites. Recorded at the 2016 National Cancer Research Institute (NCRI) Conference in Liverpool, UK.